Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy After Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 8610

A Pollack; D.J Grignon; K.H Heydon; E.H Hammond; C.A Lawton; J.B Mesic; K.K Fu; A.T Porter; R.A Abrams; W.U Shipley

doi:10.1200/JCO.2003.02.025

Back

Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy After Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 8610

Journal article

Peer reviewed

Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy After Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 8610

A Pollack, D.J Grignon, K.H Heydon, E.H Hammond, C.A Lawton, J.B Mesic, K.K Fu, A.T Porter, R.A Abrams and W.U Shipley

Journal of clinical oncology, Vol.21(7), pp.1238-1248

2003-04-01

DOI: https://doi.org/10.1200/JCO.2003.02.025

PMID: 12663710

Abstract

Purpose: DNA ploidy has consistently been found to be a correlate of prostate cancer patient outcome. However, a minority of studies have used pretreatment diagnostic material and have involved radiotherapy (RT)-treated patients. In this retrospective study, the predictive value of DNA ploidy was evaluated in patients entered into Radiation Therapy Oncology Group protocol 8610. The protocol treatment randomization was RT alone versus RT plus short-course (∼4 months) neoadjuvant and concurrent total androgen blockade (RT+TAB). Patients and Methods: The study population consisted of 149 patients, of whom 74 received RT alone and 75 received RT+TAB. DNA content was determined by image analysis of Feulgen stained tissue sections; 94 patients were diploid and 55 patients were nondiploid. Kaplan-Meier univariate survival, the cumulative incidence method, and Cox proportional hazards multivariate analyses were used to evaluate the relationship of DNA ploidy to distant metastasis and overall survival. Results: DNA nondiploidy was not associated with any of the other prognostic factors in univariate analyses. In Kaplan-Meier analyses, 5-year overall survival was 70% for those with diploid tumors and 42% for nondiploid tumors. Cox proportional hazards regression revealed that nondiploidy was independently associated with reduced overall survival. No correlation was observed between DNA ploidy and distant metastasis. The diminished survival in the absence of an increase in distant metastasis was related to a reduction in the effect of salvage androgen ablation; patients treated initially with RT+TAB and who had nondiploid tumors had reduced survival after salvage androgen ablation. Conclusions: Nondiploidy was associated with shorter survival, which seemed to be related to reduced response to salvage hormone therapy for those previously exposed to short-term TAB.

Metrics

7 Record Views

30 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.147 Prostate Cancer; 1.147.97 Prostate Cancer
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy After Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 8610
Creators: A Pollack - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
D.J Grignon - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
K.H Heydon - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
E.H Hammond - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
C.A Lawton - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
J.B Mesic - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
K.K Fu - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
A.T Porter - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
R.A Abrams - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
W.U Shipley - From the Department of Radiation Oncology, Fox Chase Cancer Center, and Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, Karmanos CA Institute, and Department of Radiation Oncology, Wayne State University, Detroit, MI; Radiation Therapy Oncology Group, Philadelphia, PA; Department of Pathology, LDS Hospital, Salt Lake City, Utah; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Radiation Oncology Center, Sacramento; and Department of Radiation
Publication Details: Journal of clinical oncology, Vol.21(7), pp.1238-1248
Academic Unit: Miller School of Medicine; Leadership Department; UMMG Dept of Radiation Oncology
Language: English
Resource Type: Journal article
PMID: 12663710
Record Identifier: 991031559529102976